- Home
- FNLC vs CRVS Comparison
FNLC vs CRVS Comparison
Compare FNLC & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FNLC
- CRVS
- Stock Information
- Founded
- FNLC 1864
- CRVS 2014
- Country
- FNLC United States
- CRVS United States
- Employees
- FNLC N/A
- CRVS N/A
- Industry
- FNLC Major Banks
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- FNLC Finance
- CRVS Health Care
- Exchange
- FNLC Nasdaq
- CRVS Nasdaq
- Market Cap
- FNLC 284.1M
- CRVS 257.0M
- IPO Year
- FNLC 1999
- CRVS 2016
- Fundamental
- Price
- FNLC $24.51
- CRVS $4.50
- Analyst Decision
- FNLC
- CRVS Strong Buy
- Analyst Count
- FNLC 0
- CRVS 5
- Target Price
- FNLC N/A
- CRVS $12.38
- AVG Volume (30 Days)
- FNLC 19.8K
- CRVS 644.9K
- Earning Date
- FNLC 04-16-2025
- CRVS 05-05-2025
- Dividend Yield
- FNLC 5.85%
- CRVS N/A
- EPS Growth
- FNLC N/A
- CRVS N/A
- EPS
- FNLC 2.43
- CRVS N/A
- Revenue
- FNLC $79,740,000.00
- CRVS N/A
- Revenue This Year
- FNLC N/A
- CRVS N/A
- Revenue Next Year
- FNLC N/A
- CRVS N/A
- P/E Ratio
- FNLC $10.23
- CRVS N/A
- Revenue Growth
- FNLC 0.35
- CRVS N/A
- 52 Week Low
- FNLC $21.77
- CRVS $1.30
- 52 Week High
- FNLC $31.05
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- FNLC 36.81
- CRVS 48.59
- Support Level
- FNLC $24.34
- CRVS $4.12
- Resistance Level
- FNLC $26.38
- CRVS $4.71
- Average True Range (ATR)
- FNLC 0.55
- CRVS 0.31
- MACD
- FNLC -0.11
- CRVS 0.09
- Stochastic Oscillator
- FNLC 8.33
- CRVS 69.70
About FNLC First Bancorp Inc (ME)
First Bancorp Inc is a Damariscotta-based bank holding company providing a range of retail and commercial banking services including deposit accounts and consumer, commercial and mortgage loans. The company provides investment management and private banking services through an operating division of the bank. Its revenues are generally derived from dividends paid to the company by the bank.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).